Don’t hold your breath for ‘Cures 2.0’
Congress’ passage of the 21st Century Cures Act, back in the waning days of the Obama administration, stands as a rare bipartisan moment for the increasingly fractious legislature. Now, an effort to get the band back together for a sequel might get derailed.
As STAT’s Nicholas Florko reports, the architects of Cures 1.0 have spent the last four months pitching a new iteration that would invest more money in medical research and, at least in theory, speed up the development of new medicines. But where the first iteration galvanized support from the drug industry, pharma is currently occupied instead “lobbying for its life” against legislation that would regulate pricing, as one lobbyist put it.
In pharma's view, progressives might also see Cures 2.0 as an ideal vehicle to enact pricing regulations, and that would leave it dead in the water when it comes to drawing the bipartisan — and industry — support that made its predecessor a success.
Read more.
As STAT’s Nicholas Florko reports, the architects of Cures 1.0 have spent the last four months pitching a new iteration that would invest more money in medical research and, at least in theory, speed up the development of new medicines. But where the first iteration galvanized support from the drug industry, pharma is currently occupied instead “lobbying for its life” against legislation that would regulate pricing, as one lobbyist put it.
In pharma's view, progressives might also see Cures 2.0 as an ideal vehicle to enact pricing regulations, and that would leave it dead in the water when it comes to drawing the bipartisan — and industry — support that made its predecessor a success.
Read more.
No hay comentarios:
Publicar un comentario